This content is only available within our institutional offering.
06 Nov 2025
Hikma Pharmaceuticals (HIK LN, Under Review) (Company Update) - M10 trading: FY25 fine, mid-term Injectables worse
Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
Hikma Pharmaceuticals (HIK LN, Under Review) (Company Update) - M10 trading: FY25 fine, mid-term Injectables worse
Hikma Pharmaceuticals Plc (HIK:LON) | 1,612 274 1.1% | Mkt Cap: 3,577m
- Published:
06 Nov 2025 -
Author:
Miles Dixon -
Pages:
9 -